Table. 1.
Patient characteristics
| All patients (n = 100) | Patients with MRI-PDFF response (≥ 30% relative decline in MRI-PDFF) (n = 25) | Patients with MRI-PDFF non-response (< 30% relative decline in MRI-PDFF) (n = 75) | p value | |
|---|---|---|---|---|
| Age (years) | 54 (43–62) | 55 (45–63) | 54 (41–60) | 0.4 |
| Weight (kg) | 89.5 (76–99) | 89.1 (80–94) | 89.7 (75–102) | 0.9 |
| BMI (kg/m2) | 31.9 (29–36) | 30.5 (28–34) | 32.5 (29–37) | 0.3 |
| Gender (women, n [%]) | 62 (62.0%) | 15 (60.0%) | 47 (62.7%) | 0.8 |
| Race, n (%) | 0.2 | |||
| White | 43 (43.0%) | 9 (36.0%) | 34 (45.3%) | |
| Hispanic | 40 (40.0%) | 10 (40.0%) | 30 (40.0%) | |
| Other | 17 (17.0%) | 6 (24.0%) | 11 (14.7%) | |
| Diabetes mellitus, n (%) | 47 (47.0%) | 12 (48.0%) | 35 (46.7%) | 1 |
| Hypertension, n (%) | 48 (48.0%) | 17 (68.0%) | 31 (41.3%) | 0.04 |
| Dyslipidemia, n (%) | 42 (42.0%) | 13 (52.0%) | 29 (38.7%) | 0.3 |
| Biochemical data | ||||
| AST (IU/L) | 35 (26–58) | 31 (26–61) | 35 (26–54) | 0.7 |
| ALT (IU/L) | 45 (32–77) | 44 (31–75) | 47 (36–77) | 0.6 |
| ALP (IU/L) | 73 (61–87) | 76 (57–87) | 72 (62–87) | 0.9 |
| GGT (IU/L) | 40 (28–63) | 39 (27–49) | 41 (28–65) | 0.5 |
| Bilirubin (mg/dl) | 0.4 (0.3–0.6) | 0.5 (0.4–0.6) | 0.4 (0.3–0.6) | 0.7 |
| Total cholesterol (mg/dl) | 182 (155–200) | 182 (151–195) | 181 (156–201) | 0.9 |
| HDL (mg/dl) | 43 (36–54) | 43 (39–52) | 43 (35–55) | 0.4 |
| LDL (mg/dl) | 98 (81–124) | 102 (81–129) | 97 (81–124) | 0.7 |
| TG (mg/dl) | 145 (111–197) | 147 (117–175) | 145 (111–198) | 0.7 |
| Platelet count (109/L) | 247 (198–278) | 239 (207–263) | 249 (196–280) | 0.6 |
| HbA1c (%) | 6.0 (5.6–6.6) | 6.0 (5.7–6.7) | 5.0 (5.6–6.6) | 0.9 |
| Interval between biopsies (years) | 1.4 (0.6–2.9) | 1.4 (0.6–3.1) | 1.4 (0.7–2.5) | 0.8 |
| Histological findings* | ||||
| Fibrosis stage, n (%) | 0.7 | |||
| 0 | 27 (27.0%) | 9 (36.0%) | 18 (24.0%) | |
| 1 | 35 (35.0%) | 7 (28.0%) | 28 (37.3%) | |
| 2 | 12 (12.0%) | 2 (8.0%) | 10 (13.3%) | |
| 3 | 16 (16.0%) | 4 (16.0%) | 12 (16.0%) | |
| 4 | 10 (10.0%) | 3 (12.0%) | 7 (9.3%) | |
| Steatosis grade (0/1/2/3) | 0.8 | |||
| 0 | 1 (1.0%) | 0 (0%) | 1 (1.3%) | |
| 1 | 34 (34.0%) | 8 (32.0% | 26 (34.7%) | |
| 2 | 40 (40.0%) | 12 (48.0%) | 28 (37.3%) | |
| 3 | 25 (25.0%) | 5 (20.0%) | 20 (26.7%) | 0.8 |
| Lobular inflammation (0/1/2/3) | ||||
| 0 | 0 (0%) | 0 (0%) | 0 (0%) | |
| 1 | 39 (39.0%) | 8 (32.0%) | 31 (41.3%) | |
| 2 | 56 (56.0%) | 16 (64.0%) | 40 (53.3%) | |
| 3 | 5 (5.0%) | 1 (4.0%) | 4 (5.3%) | |
| Ballooning grade (0/1/2) | 0.3 | |||
| 0 | 10 (10.0%) | 4 (16.0%) | 6 (8.0%) | |
| 1 | 56 (56.0%) | 11 (44.0%) | 45 (60.0%) | |
| 2 | 34 (34.0%) | 10 (40.0%) | 24 (32.0%) | |
| NAS | 5 (4–6) | 5 (4–6) | 5 (4–6) | 0.7 |
| MRI findings | ||||
| PDFF (%) | 14.2 (9.1–19.5) | 12.6 (9.3–18.0) | 14.4 (8.9–19.7) | 0.9 |
| Liver stiffness (kPa) | 2.92 (2.49–3.89) | 2.88 (2.35–3.89) | 2.99 (2.53–3.83) | 0.5 |
Data are shown in median (interquartile range).
MRI-PDFF response and non-response are defined as ≥ 30% relative decline and < 30% relative decline in MRI-PDFF.
*
NASH CRN histology scoring system is used.
P value indicates difference between patients with MRI-PDFF response and those with MRI-PDFF non-response.
BMI, body mass index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase, GGT, gamma glutamyl transferase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglycerides; HbA1c, hemoglobin A1c; NAS, nonalcoholic fatty liver disease activity score; MRI, magnetic resonance imaging; PDFF, proton density fat fraction